EdiGene is a genome-editing company, possessing efficient genome-editing techniques, advanced high-throughput genetic screening platform, and ready-made knock-out cell lines. EdiGene dedicates to server the biomedical companies, diagnostic companies, and R&D groups with rich genome editing experience. At the same time, EdiGene cooperate with hospitals and medical companies to develop new therapeutics for cancers, genetic diseases and infectious disease.
The core members of EdiGene graduated from Peking University, Stanford University, Cornell University, etc. They have genome editing related papers published on Nature, Nature Biotechnology, Cell Research, etc. and possess a lot of related patents.
EdiGene provides KO cell lines, KO cell lysates as standards for antibody companies to guarantee high quality of their products. EdiGene takes the high-throughput genetic screening platform to assist biomedical companies in finding out drug targets and precision drug use. Edigene supports R&D groups with validated genome editing tools, including sgRNAs, Cas9 expressing cell lines, etc. There are more than 1,600 （the number is growing rapidly）ready-made KO cell lines available in EdiGene for researchers worldwide. Also, EdiGene efficiently fulfill demands for the other genome edited cell lines.